Overview
| Generic Names: | MOF; Methoflurane; Methoxiflurane; Methoxifluranum; Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum [INN-Latin]; Metossiflurano [Dcit]; Metoxfluran; Metoxifluran; Metoxiflurano [INN-Spanish] |
|---|---|
| Trade Names: | Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoxane; Metofane; Penthrane; Pentran; Pentrane |
| PharmGKB Accession Id: | PA450434 |
Description
An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) (source: Drug Bank)
Indication
For use in the induction and maintenance of general anesthesia (source: Drug Bank)
ATC Therapeutic Category
- N01AB:Halogenated hydrocarbons
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Methoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor. (source: Drug Bank)
Pharmacology
Methoxyflurane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic. (source: Drug Bank)
Toxicity
LD<sub>50</sub>=3600 mg/kg (Orally in rats). Symptoms of overexposure include eye irritation, CNS depression, analgesia, anesthesia, seizures, respiratory depression, and liver and kidney damage. (source: Drug Bank)
Isomeric SMILES Code:
COC(C(Cl)Cl)(F)F (source: Drug Bank)
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| ATP5D |
|
(source: Drug Bank) |
| ATP2C1 |
|
(source: Drug Bank) |
| CYB5A |
|
(source: Drug Bank) |
| GABRA1 |
|
(source: Drug Bank) |
| GRIA1 |
|
(source: Drug Bank) |
| GLRA1 |
|
(source: Drug Bank) |
| MT-ND1 |
|
(source: Drug Bank) |
| KCNA1 |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
